Venator Materials PLC

Period selection. The last five publicly reported fiscal years are FY2018–FY2022. FY2023–FY2025 consolidated statements are not publicly disclosed (SEC deregistration followed Chapter 11; the company entered administration before any later public reporting located). An aggregator (Parqet) cites "last year" revenue of ~USD 2.03bn and net income of ~USD 169m; this is unsourced, inconsistent with the operating record, and is not relied upon — discrepancy flagged.

All figures USD millions unless stated; Sources: Form 10-K FY2020 (FY2018–2020 income statement lines), Q4/FY2022 results presentation and releases (FY2021–2022, EBITDA reconciliation 2017–2022).

Income statement

Operating income, statutory EBITDA, pre-tax income and basic/diluted EPS for each year are in the filings but were not all retrieved and verified; they are therefore left blank rather than estimated. FY2021 diluted loss per share was USD –0.72 (FY2021 release). Venator never paid an ordinary dividend.

Margins (derived from table 6.1)

Revenue CAGR FY2018–FY2022: approximately –1.0% per annum (2,265 → 2,173). Using the 2018 peak, adjusted EBITDA fell by ~88% over four years.

Balance sheet

Verified balance-sheet-relevant data points:

Cash flow

Q4 2019 operating cash flow was USD 69m and free cash flow USD 20m; Q4 2019 capex USD 42m (FY2019 release). No share buybacks of note were executed (no authorisation located).

Ratios

ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle cannot be computed without verified balance-sheet data and are therefore not publicly verified. Directionally: with funded debt above USD 1bn and FY2022 adjusted EBITDA of USD 53m, leverage exceeded 19x adjusted EBITDA entering 2023 — the arithmetic that made the Chapter 11 equitisation unavoidable.

Commentary — trends, inflections and drivers

2018 peak. FY2018 adjusted EBITDA of USD 436m reflected the tail of the 2017–18 TiO2 price upcycle, but statutory results were already loss-making because of Pori-related impairments and plant-closure charges. The divergence between "adjusted" profitability (USD 235m adjusted net income) and statutory losses (USD –157m) is the key early-warning sign in the record: the business was persistently booking restructuring, impairment and incident costs.

2019–2020 decline. Revenue fell 6% in 2019 and 9% in 2020; the gross margin compressed from 31.6% to 8.3%. The 2019 net loss was inflated by a USD 157m deferred-tax valuation allowance — an accounting signal that management no longer expected sufficient UK/European taxable profits. Cost programmes (USD 20m in 2019, USD 57m in 2020) cushioned but could not reverse the decline.

2021 recovery. Revenue recovered 14% to USD 2,212m and adjusted EBITDA to USD 180m on price recovery, but the company still recorded a net loss attributable of USD 77m — even at a cyclical recovery Venator could not deliver statutory profit.

2022 collapse. Despite revenue of USD 2,173m (prices high in H1), the energy shock following the Russian invasion of Ukraine, European destocking and Chinese export pressure drove Q3 and Q4 adjusted EBITDA negative (–USD 8m and –USD 57m). Net loss attributable reached USD 188m, including a USD 111m impairment on the iron oxide disposal group. This inflection directly triggered the 2023 recapitalisation.

2023–2025 (not publicly disclosed). No consolidated figures are public. Qualitatively, the administrators attributed the 2025 failure to increased competition and rising costs; German press tied the insolvencies to energy and raw-material inflation; and the Greatham plant was idled before sale. These facts are consistent with continued losses through 2024–25.

Management guidance

None. The administrators' stated objective is to realise value and wind down the wider Venator Group.

Consensus growth expectations

Not applicable — no coverage and no going-concern operating plan.

Bull-case arguments (for creditor recoveries, not equity)

1. Asset realisations exceeded liquidation scenarios. Greatham (USD 69.9m), Duisburg (going concern, 350 jobs), Scarlino and Huelva were all sold to strategic buyers rather than scrapped, indicating meaningful recovery values.

2. Residual receivables. The LPC earn-out (up to USD 15m, measured on Kronos 2025–26 EBITDA) could crystallise in 2027.

3. Remaining going concerns. The US and French businesses, and potentially Venator Asia post-scheme, may still be sold, adding recovery value.

Bear-case arguments

1. Claims far exceed realisations. Reported creditor claims above £600m set against disclosed proceeds that appear substantially lower imply large shortfalls for unsecured creditors.

2. Liability tail. Closed sites (Uerdingen, former Duisburg TiO2, Pori) carry environmental, decommissioning and pension liabilities that are not quantified publicly.

3. No equity value. Shareholders were wiped out in 2023, and post-emergence equity sits behind creditors in administration; any OTC quotation does not reflect recoverable value.

Catalysts and monitorables (next 12 months)

• Administrators' progress reports (England & Wales) — realisations, dividend prospects for creditors.

• Outcome of the Venator Asia Sdn Bhd scheme of arrangement.

• Sale or wind-down of Venator Americas and French entities.

• LPC earn-out determination (Kronos FY2026 results, early 2027).

• LB Group's restart of Greatham and the UK TRA decision on Chinese rutile TiO2.

• Any dissolution/exit-from-administration filings for Venator Materials PLC.

Analyst verdict

Venator Materials PLC should now be analysed as an insolvency estate rather than an investable enterprise. The equity story ended in May 2023, when the prepackaged Chapter 11 cancelled legacy shares; the post-emergence creditor-owners then saw their recapitalised company fail within two years. The financial record explains why. Across FY2018–FY2022, Venator never produced a statutory profit, adjusted EBITDA margins collapsed from 19.2% to 2.4%, and revenue drifted down at about 1% a year even through a cyclical recovery. Its European-heavy, predominantly sulfate-process footprint, lack of feedstock integration and single chloride site left it the highest-cost large Western producer as China added capacity and European energy costs spiked after 2022.

The 2023 debt reset was necessary but not sufficient. It reduced funded debt from over USD 1bn to around USD 200m, yet the 2024 transformation plan — closing Duisburg TiO2, keeping Scarlino offline and selling the LPC stake — merely shrank the business without fixing its cost position. When TiO2 prices stayed depressed through 2025, liquidity ran out; administration followed, and the group's plants were dispersed to LB Group, ICIG, Nuova Solmine and Indorama, with Uerdingen closed outright.

There is a coherent industrial logic to where the assets went: the highest-value pieces (Greatham's chloride technology, Duisburg's specialty additives, Huelva) found strategic owners, and trade remedies in the EU and UK may now support those plants under new management. That is a positive outcome for the regions and some employees, but it accrues to the buyers, not to Venator's stakeholders.

For credit and restructuring professionals, the focus should be on administrators' reports, the Malaysian scheme, the remaining US and French businesses, and the LPC earn-out. For equity investors, there is nothing to underwrite. The dossier's conclusion is unambiguous: no investment case exists; monitor only for creditor recoveries and as a case study in European TiO2 deindustrialisation.